Chemistry Reference
In-Depth Information
can rapidly enable an understanding of the SAR to drive decisions and direc-
tions for the program. Our willingness to tackle synthetically challenging
azabicyclic amines and heterocycles was equally important in designing novel
compounds with the right pharmacological and safety profiles. With the right
pharmacologic tools in hand, we were able to identify ecacy and safety
markers early in a program, which increased our understanding of the trans-
lational pharmacology into a clinical setting. Even with this success, however,
surprises did occur with PHA-543613, and backup compounds were necessary
to address those issues. Not every successful clinical entry results in the iden-
tification of a new medicine for the patients that our teams would like to help,
but each attempt refines our techniques for the pursuit of safe molecules with
which to test hypotheses.
References
1. Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportu-
nities, ed. S. P. Arneric and J. D. Brioni, Wiley-Liss, New York, 1999.
2. Handbook of Experimental Pharmacology: Neuronal: Neuronal Nicotinic
Receptors, ed. F. Clementi, D. Fornasari and C. Gotti, Springer, Berlin,
2000.
3. For nAChR lead references, see: (a) A. Taly, P.-J. Corringer, D. Guedin, P.
Lestage and J.-P. Changeux, Nat. Rev. Drug Discovery, 2009, 8, 733; (b) M.
R. Picciotto, B. J. Caldarone, S. L. King and V. Zachariou, Neu-
ropsychopharmacology, 2000, 22, 451; (c) J. A. Dani, Biol. Psychiatry, 2001,
49, 166.
4. R. J. Lukas, J.-P. Changeux, N. Le Nove` re, E. X. Albuquerque, D. J. K.
Balfour, D. K. Berg, D. Bertrand, V. A. Chiappinelli, P. B. S. Clarke, A. C.
Collins, J. A. Dani, S. R. Grady, K. J. Kellar, J. M. Lindstrom, M. J.
Marks, M. Quik, P. W. Taylor and S. Wonnacott, Pharmacol. Rev., 1999,
51, 397.
5. (a) J. A. Dani and D. Bertrand, Annu. Rev. Pharmacol. Toxicol., 2007, 47,
699; (b) C. Ulens, A. Akdemir, A. Jongejan, R. van Elk, S. Bertrand, A.
Perrakis, R. Leurs, A. B. Smit, T. K. Sixma, D. Bertrand and I. J. P. de
Esch, J. Med. Chem., 2009, 52, 2372.
6. S. Weiland, D. Bertrand and S. Leonard, Behav. Brain Res., 2000,
113, 43.
7. (a) P. Se´ gue´ la, J. Wadiche, K. Dineley-Miller, J. A. Dani and J. W. Patrick,
J. Neurosci., 1993, 13, 596; (b) E. D. Levin and B. B. Simon, Psycho-
pharmacology, 1998, 138, 217.
8. L. E. Adler, A. Olincy, M. Waldo, J. G. Harris, J. Grith, K. Stevens, K.
Flach, H. Nagamoto, P. Bickford, S. Leonard and R. Freedman, Schi-
zophr. Bull., 1998, 24, 189.
9. (a) L. E. Adler, L. D. Hoffer, A. Wiser and R. Freedman, Am. J. Psy-
chiatry, 1993, 150, 1856; (b) K. E. Stevens, W. R. Kem, V. M. Mahnir and
R. Freedman, Psychopharmacology, 1998, 136, 320.
Search WWH ::
Custom Search